Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Immunotherapy, 2019-01, Vol.68 (1), p.1-9
Hauptverfasser: Maio, Michele, Coukos, George, Ferrone, Soldano, Fox, Bernard A., Fridman, Wolf H., Garcia, Patrick L., Lahn, Michael, Provendier, Olivier, Russo, Vincenzo, Rüttinger, Dominik, Shalabi, Aiman, Trajanoski, Zlatko, Viallet, Jean, Wolchok, Jedd D., Ibrahim, Ramy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9
container_issue 1
container_start_page 1
container_title Cancer Immunology, Immunotherapy
container_volume 68
creator Maio, Michele
Coukos, George
Ferrone, Soldano
Fox, Bernard A.
Fridman, Wolf H.
Garcia, Patrick L.
Lahn, Michael
Provendier, Olivier
Russo, Vincenzo
Rüttinger, Dominik
Shalabi, Aiman
Trajanoski, Zlatko
Viallet, Jean
Wolchok, Jedd D.
Ibrahim, Ramy
description A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.
doi_str_mv 10.1007/s00262-018-2285-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11028087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2158557338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-44e4a722c587d13e059aea341699d92f1f46f763ac966126a3d50363239b22043</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EotPCA7BBltiwaOD4ksRhg0pFYaQKFgxry3VOZtwm9tROKvIcfWE8nVIuEhvbsr_z-xx9hLxg8IYB1G8TAK94AUwVnKuymB-RBZMi36iSPSYLEBKKGkAekMOULvOBQ9M8JQcCykoq1SzI7UnbRkzJ-TW1U4zoR2o3pu_RrzFR41vaTeMUkbYuoh1d8Ik6T90wTD4UwdvQh_X8juKPLcaR5iVtd9xNru5iGOi4QcqB1fTL8sNyRc_C5Fuzy6GrjfNXdGX81TH95tCbY7ocTT8_I0860yd8fr8fke9nH1enn4vzr5-WpyfnhZVcjYWUKE3NuS1V3TKBUDYGjZCsapq24R3rZNXVlTC2qSrGKyPaEkQluGguOAcpjsj7fe52uhiwtXn2aHq9jW4wcdbBOP33i3cbvQ43mjHgClSdE17fJ8RwPWEa9eCSxb43HsOUNGelKstaCJXRV_-gl2GKPs93R2Uh9V1LbE_ZGFKK2D10w0DvnOu9c52d651zPeeal3-O8VDxS3IG-B5I-Slrjb-__n_qTzzIuEU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2158056704</pqid></control><display><type>article</type><title>Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Maio, Michele ; Coukos, George ; Ferrone, Soldano ; Fox, Bernard A. ; Fridman, Wolf H. ; Garcia, Patrick L. ; Lahn, Michael ; Provendier, Olivier ; Russo, Vincenzo ; Rüttinger, Dominik ; Shalabi, Aiman ; Trajanoski, Zlatko ; Viallet, Jean ; Wolchok, Jedd D. ; Ibrahim, Ramy</creator><creatorcontrib>Maio, Michele ; Coukos, George ; Ferrone, Soldano ; Fox, Bernard A. ; Fridman, Wolf H. ; Garcia, Patrick L. ; Lahn, Michael ; Provendier, Olivier ; Russo, Vincenzo ; Rüttinger, Dominik ; Shalabi, Aiman ; Trajanoski, Zlatko ; Viallet, Jean ; Wolchok, Jedd D. ; Ibrahim, Ramy</creatorcontrib><description>A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-018-2285-y</identifier><identifier>PMID: 30564889</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biomarkers, Tumor - blood ; Cancer immunotherapy ; Cancer Research ; Collaboration ; Diffusion of Innovation ; Humans ; Immunology ; Immunotherapy - methods ; Immunotherapy - trends ; Italy ; Medical Oncology - methods ; Medical Oncology - trends ; Medicine ; Medicine &amp; Public Health ; Neoplasms - blood ; Neoplasms - immunology ; Neoplasms - therapy ; Oncology ; Opinion Paper ; PD-1 protein ; PD-L1 protein ; Pharmaceutical industry ; Think tanks ; Translation ; Translational Research, Biomedical - methods ; Translational Research, Biomedical - trends</subject><ispartof>Cancer Immunology, Immunotherapy, 2019-01, Vol.68 (1), p.1-9</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Cancer Immunology, Immunotherapy is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-44e4a722c587d13e059aea341699d92f1f46f763ac966126a3d50363239b22043</citedby><cites>FETCH-LOGICAL-c428t-44e4a722c587d13e059aea341699d92f1f46f763ac966126a3d50363239b22043</cites><orcidid>0000-0003-2900-8834 ; 0000-0001-8813-7367 ; 0000-0002-4452-5947 ; 0000-0001-6718-2222 ; 0000-0003-1592-5041 ; 0000-0002-0323-6321 ; 0000-0002-0636-7351 ; 0000-0002-1332-0973</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028087/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028087/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,309,310,314,727,780,784,789,790,885,23930,23931,25140,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30564889$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maio, Michele</creatorcontrib><creatorcontrib>Coukos, George</creatorcontrib><creatorcontrib>Ferrone, Soldano</creatorcontrib><creatorcontrib>Fox, Bernard A.</creatorcontrib><creatorcontrib>Fridman, Wolf H.</creatorcontrib><creatorcontrib>Garcia, Patrick L.</creatorcontrib><creatorcontrib>Lahn, Michael</creatorcontrib><creatorcontrib>Provendier, Olivier</creatorcontrib><creatorcontrib>Russo, Vincenzo</creatorcontrib><creatorcontrib>Rüttinger, Dominik</creatorcontrib><creatorcontrib>Shalabi, Aiman</creatorcontrib><creatorcontrib>Trajanoski, Zlatko</creatorcontrib><creatorcontrib>Viallet, Jean</creatorcontrib><creatorcontrib>Wolchok, Jedd D.</creatorcontrib><creatorcontrib>Ibrahim, Ramy</creatorcontrib><title>Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.</description><subject>Biomarkers, Tumor - blood</subject><subject>Cancer immunotherapy</subject><subject>Cancer Research</subject><subject>Collaboration</subject><subject>Diffusion of Innovation</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy - methods</subject><subject>Immunotherapy - trends</subject><subject>Italy</subject><subject>Medical Oncology - methods</subject><subject>Medical Oncology - trends</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Oncology</subject><subject>Opinion Paper</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Pharmaceutical industry</subject><subject>Think tanks</subject><subject>Translation</subject><subject>Translational Research, Biomedical - methods</subject><subject>Translational Research, Biomedical - trends</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kctu1DAUhi0EotPCA7BBltiwaOD4ksRhg0pFYaQKFgxry3VOZtwm9tROKvIcfWE8nVIuEhvbsr_z-xx9hLxg8IYB1G8TAK94AUwVnKuymB-RBZMi36iSPSYLEBKKGkAekMOULvOBQ9M8JQcCykoq1SzI7UnbRkzJ-TW1U4zoR2o3pu_RrzFR41vaTeMUkbYuoh1d8Ik6T90wTD4UwdvQh_X8juKPLcaR5iVtd9xNru5iGOi4QcqB1fTL8sNyRc_C5Fuzy6GrjfNXdGX81TH95tCbY7ocTT8_I0860yd8fr8fke9nH1enn4vzr5-WpyfnhZVcjYWUKE3NuS1V3TKBUDYGjZCsapq24R3rZNXVlTC2qSrGKyPaEkQluGguOAcpjsj7fe52uhiwtXn2aHq9jW4wcdbBOP33i3cbvQ43mjHgClSdE17fJ8RwPWEa9eCSxb43HsOUNGelKstaCJXRV_-gl2GKPs93R2Uh9V1LbE_ZGFKK2D10w0DvnOu9c52d651zPeeal3-O8VDxS3IG-B5I-Slrjb-__n_qTzzIuEU</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Maio, Michele</creator><creator>Coukos, George</creator><creator>Ferrone, Soldano</creator><creator>Fox, Bernard A.</creator><creator>Fridman, Wolf H.</creator><creator>Garcia, Patrick L.</creator><creator>Lahn, Michael</creator><creator>Provendier, Olivier</creator><creator>Russo, Vincenzo</creator><creator>Rüttinger, Dominik</creator><creator>Shalabi, Aiman</creator><creator>Trajanoski, Zlatko</creator><creator>Viallet, Jean</creator><creator>Wolchok, Jedd D.</creator><creator>Ibrahim, Ramy</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2900-8834</orcidid><orcidid>https://orcid.org/0000-0001-8813-7367</orcidid><orcidid>https://orcid.org/0000-0002-4452-5947</orcidid><orcidid>https://orcid.org/0000-0001-6718-2222</orcidid><orcidid>https://orcid.org/0000-0003-1592-5041</orcidid><orcidid>https://orcid.org/0000-0002-0323-6321</orcidid><orcidid>https://orcid.org/0000-0002-0636-7351</orcidid><orcidid>https://orcid.org/0000-0002-1332-0973</orcidid></search><sort><creationdate>20190101</creationdate><title>Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy</title><author>Maio, Michele ; Coukos, George ; Ferrone, Soldano ; Fox, Bernard A. ; Fridman, Wolf H. ; Garcia, Patrick L. ; Lahn, Michael ; Provendier, Olivier ; Russo, Vincenzo ; Rüttinger, Dominik ; Shalabi, Aiman ; Trajanoski, Zlatko ; Viallet, Jean ; Wolchok, Jedd D. ; Ibrahim, Ramy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-44e4a722c587d13e059aea341699d92f1f46f763ac966126a3d50363239b22043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers, Tumor - blood</topic><topic>Cancer immunotherapy</topic><topic>Cancer Research</topic><topic>Collaboration</topic><topic>Diffusion of Innovation</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy - methods</topic><topic>Immunotherapy - trends</topic><topic>Italy</topic><topic>Medical Oncology - methods</topic><topic>Medical Oncology - trends</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Oncology</topic><topic>Opinion Paper</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Pharmaceutical industry</topic><topic>Think tanks</topic><topic>Translation</topic><topic>Translational Research, Biomedical - methods</topic><topic>Translational Research, Biomedical - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maio, Michele</creatorcontrib><creatorcontrib>Coukos, George</creatorcontrib><creatorcontrib>Ferrone, Soldano</creatorcontrib><creatorcontrib>Fox, Bernard A.</creatorcontrib><creatorcontrib>Fridman, Wolf H.</creatorcontrib><creatorcontrib>Garcia, Patrick L.</creatorcontrib><creatorcontrib>Lahn, Michael</creatorcontrib><creatorcontrib>Provendier, Olivier</creatorcontrib><creatorcontrib>Russo, Vincenzo</creatorcontrib><creatorcontrib>Rüttinger, Dominik</creatorcontrib><creatorcontrib>Shalabi, Aiman</creatorcontrib><creatorcontrib>Trajanoski, Zlatko</creatorcontrib><creatorcontrib>Viallet, Jean</creatorcontrib><creatorcontrib>Wolchok, Jedd D.</creatorcontrib><creatorcontrib>Ibrahim, Ramy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maio, Michele</au><au>Coukos, George</au><au>Ferrone, Soldano</au><au>Fox, Bernard A.</au><au>Fridman, Wolf H.</au><au>Garcia, Patrick L.</au><au>Lahn, Michael</au><au>Provendier, Olivier</au><au>Russo, Vincenzo</au><au>Rüttinger, Dominik</au><au>Shalabi, Aiman</au><au>Trajanoski, Zlatko</au><au>Viallet, Jean</au><au>Wolchok, Jedd D.</au><au>Ibrahim, Ramy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>68</volume><issue>1</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30564889</pmid><doi>10.1007/s00262-018-2285-y</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2900-8834</orcidid><orcidid>https://orcid.org/0000-0001-8813-7367</orcidid><orcidid>https://orcid.org/0000-0002-4452-5947</orcidid><orcidid>https://orcid.org/0000-0001-6718-2222</orcidid><orcidid>https://orcid.org/0000-0003-1592-5041</orcidid><orcidid>https://orcid.org/0000-0002-0323-6321</orcidid><orcidid>https://orcid.org/0000-0002-0636-7351</orcidid><orcidid>https://orcid.org/0000-0002-1332-0973</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology, Immunotherapy, 2019-01, Vol.68 (1), p.1-9
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11028087
source MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings
subjects Biomarkers, Tumor - blood
Cancer immunotherapy
Cancer Research
Collaboration
Diffusion of Innovation
Humans
Immunology
Immunotherapy - methods
Immunotherapy - trends
Italy
Medical Oncology - methods
Medical Oncology - trends
Medicine
Medicine & Public Health
Neoplasms - blood
Neoplasms - immunology
Neoplasms - therapy
Oncology
Opinion Paper
PD-1 protein
PD-L1 protein
Pharmaceutical industry
Think tanks
Translation
Translational Research, Biomedical - methods
Translational Research, Biomedical - trends
title Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A25%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addressing%20current%20challenges%20and%20future%20directions%20in%20immuno-oncology:%20expert%20perspectives%20from%20the%202017%20NIBIT%20Foundation%20Think%20Tank,%20Siena,%20Italy&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Maio,%20Michele&rft.date=2019-01-01&rft.volume=68&rft.issue=1&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-018-2285-y&rft_dat=%3Cproquest_pubme%3E2158557338%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2158056704&rft_id=info:pmid/30564889&rfr_iscdi=true